The YCC internal and external advisory groups have provided invaluable guidance in planning and evaluation of all the major initiatives since the last NCI CCSG review, particularly during the last three years since the appointment of Dr. Lynch as Director. The Director has modified and improved the network of decision-making and advisory groups to include: ? The Director's Mini-Cabinet (Mini-Cab) is composed of the Director, Deputy Directors, and Associate Directors and meets weekly to evaluate progress in strategic YCC initiatives. ? The Executive Committee meets weekly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the Mini-Cab members. ? The Internal Advisory Board, comprised of three senior leaders from the Yale School of Medicine, meets periodically with the Director to review pivotal YCC activities. ? The External Scientific Advisory Board (ESAB) has been expanded with the addition of several experienced Cancer Center leaders and includes 16 members, with complementary expertise in basic, translational, and population sciences. In addition, on the advice of the ESAB we have developed and are continually refining a Strategic Plan. With careful planning and evaluation by advisory groups, the YCC has successfully initiated the Strategic Plan, the reorganization of the Research Programs and their leadership, the integration of the new Smilow Cancer Hospital, and the substantial improvements in the clinical trials infrastructure. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that the YCC can most effectively set priorities and pursue objectives that help shape of basic, clinical, prevention and translational research at Yale.
Program Planning and Evaluation is crucial to the effective functioning and long-term strategic planning of the YCC. Input and guidance from external and internal advisory groups has encouraged the growth of the Center during the project period and will continue to develop the YCC's strengths moving forward.
|Wimberly, Hallie; Brown, Jason R; Schalper, Kurt et al. (2015) PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 3:326-32|
|Ma, Xiaomei; Wang, Rong; Long, Jessica B et al. (2014) The cost implications of prostate cancer screening in the Medicare population. Cancer 120:96-102|
|Herbst, Roy S; Soria, Jean-Charles; Kowanetz, Marcin et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7|
|Durazzo, Tyler S; Tigelaar, Robert E; Filler, Renata et al. (2014) Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus Apher Sci 50:370-8|
|Black, Jonathan D; English, Diana P; Roque, Dana M et al. (2014) Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) 10:45-57|
|Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50|
|Cao, Jian; Liu, Zongzhi; Cheung, William K C et al. (2014) Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep 6:868-77|
|Gonzalez, A L; Berger, C L; Remington, J et al. (2014) Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clin Exp Immunol 175:449-57|
|O'Malley, Stephanie S; Wu, Ran; Mayne, Susan T et al. (2014) Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 16:1145-9|
|Chen, Lieping (2014) From the guest editor: Tumor site immune modulation therapy. Cancer J 20:254-5|
Showing the most recent 10 out of 72 publications